secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001628280-23-037096
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q3 revenue beats; raises 2023 guidance to $47-50M; net loss narrows to $2.0M
--------------------------------------------------------------------------------

- Total Q3 revenue $13.0M vs $11.5M YoY; adjusted for Sympazan out-license, revenue up 42% to $13.0M from $9.2M.
- Net loss narrowed to $2.0M ($0.03/share) from $12.5M ($0.23/share); non-GAAP adjusted EBITDA loss improved to $1.3M from $7.7M.
- Full-year 2023 revenue guidance raised to $47-50M (prior $44-48M); non-GAAP adjusted EBITDA loss guidance improved to $14-17M (prior $19-22M).
- Issued $45M 13.5% Senior Secured Notes due 2028, redeeming prior 12.5% notes, resulting in ~$28M cash savings through June 2025.
- Anaphylm pivotal PK study on track for Q4 2023 start with topline data Q1 2024; Libervant NDA for ages 2-5 has PDUFA date April 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/0001628280-23-037096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/aqst-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer